Ward Yancey D, Thomson David S, Frye Leah L, Cywin Charles L, Morwick Tina, Emmanuel Michel J, Zindell Renée, McNeil Daniel, Bekkali Younes, Girardot Marc, Hrapchak Matt, DeTuri Molly, Crane Kathy, White Della, Pav Susan, Wang Yong, Hao Ming-Hong, Grygon Christine A, Labadia Mark E, Freeman Dorothy M, Davidson Walter, Hopkins Jerry L, Brown Maryanne L, Spero Denice M
Boehringer Ingelheim Pharmaceuticals, Inc. 900 Ridgebury Road, P.O. Box 368, Ridgefield, Connecticut 06877-0368, USA.
J Med Chem. 2002 Dec 5;45(25):5471-82. doi: 10.1021/jm020209i.
The specificity of the immune response relies on processing of foreign proteins and presentation of antigenic peptides at the cell surface. Inhibition of antigen presentation, and the subsequent activation of T-cells, should, in theory, modulate the immune response. The cysteine protease Cathepsin S performs a fundamental step in antigen presentation and therefore represents an attractive target for inhibition. Herein, we report a series of potent and reversible Cathepsin S inhibitors based on dipeptide nitriles. These inhibitors show nanomolar inhibition of the target enzyme as well as cellular potency in a human B cell line. The first X-ray crystal structure of a reversible inhibitor cocrystallized with Cathepsin S is also reported.
免疫反应的特异性依赖于外源蛋白的加工处理以及抗原肽在细胞表面的呈递。理论上,抑制抗原呈递以及随后的T细胞激活应能调节免疫反应。半胱氨酸蛋白酶组织蛋白酶S在抗原呈递过程中发挥着关键作用,因此是一个颇具吸引力的抑制靶点。在此,我们报道了一系列基于二肽腈的高效可逆组织蛋白酶S抑制剂。这些抑制剂对目标酶的抑制活性达纳摩尔级别,并且在人B细胞系中具有细胞活性。本文还报道了首个与组织蛋白酶S共结晶的可逆抑制剂的X射线晶体结构。